Have a feature idea you'd love to see implemented?
Let us know!
TEVA Teva Pharmaceutical Industries Ltd
Price (delayed)
$17.08
Market cap
$19.35B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.88
Enterprise value
$35.31B
Highlights
The gross profit rose by 19% year-on-year and by 3.7% since the previous quarter
TEVA's revenue is up by 10% year-on-year and by 3% since the previous quarter
Teva Pharmaceutical Industries's EPS has shrunk by 105% QoQ but it has surged by 58% YoY
TEVA's net income has dropped by 104% since the previous quarter but it has surged by 58% year-on-year
Teva Pharmaceutical Industries's equity has decreased by 12% YoY and by 4.6% QoQ
Key stats
What are the main financial stats of TEVA
Market
Valuations
Earnings
Shares outstanding
1.13B
Market cap
$19.35B
Enterprise value
$35.31B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.19
Price to sales (P/S)
1.15
EV/EBIT
49.94
EV/EBITDA
20.03
EV/Sales
2.11
Revenue
$16.77B
EBIT
$707M
EBITDA
$1.76B
Free cash flow
$1.37B
Per share
Balance sheet
Liquidity
EPS
-$0.88
Free cash flow per share
$1.21
Book value per share
$5.35
Revenue per share
$14.8
TBVPS
$18.43
Total assets
$41.76B
Total liabilities
$35.38B
Debt
$19.28B
Equity
$6.06B
Working capital
-$1.48B
Debt to equity
3.18
Current ratio
0.89
Quick ratio
0.49
Net debt/EBITDA
9.05
Margins
Efficiency
Dividend
EBITDA margin
10.5%
Gross margin
49.8%
Net margin
-5.9%
Operating margin
2.6%
Return on assets
-2.3%
Return on equity
-14.6%
Return on invested capital
2.9%
Return on capital employed
2.5%
Return on sales
4.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TEVA stock price
How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
0.29%
1 week
1.97%
1 month
-6.05%
1 year
84.25%
YTD
63.6%
QTD
-5.22%
Financial performance
How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$16.77B
Gross profit
$8.36B
Operating income
$429M
Net income
-$993M
Gross margin
49.8%
Net margin
-5.9%
TEVA's operating income has soared by 133% YoY but it is down by 49% from the previous quarter
The operating margin has soared by 131% YoY but it fell by 49% QoQ
TEVA's net income has dropped by 104% since the previous quarter but it has surged by 58% year-on-year
The net margin has dropped by 97% since the previous quarter but it has surged by 61% year-on-year
Growth
What is Teva Pharmaceutical Industries's growth rate over time
Valuation
What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
3.19
P/S
1.15
EV/EBIT
49.94
EV/EBITDA
20.03
EV/Sales
2.11
Teva Pharmaceutical Industries's EPS has shrunk by 105% QoQ but it has surged by 58% YoY
TEVA's price to book (P/B) is 128% higher than its 5-year quarterly average of 1.4 and 28% higher than its last 4 quarters average of 2.5
Teva Pharmaceutical Industries's equity has decreased by 12% YoY and by 4.6% QoQ
The P/S is 64% above the 5-year quarterly average of 0.7 and 15% above the last 4 quarters average of 1.0
TEVA's revenue is up by 10% year-on-year and by 3% since the previous quarter
Efficiency
How efficient is Teva Pharmaceutical Industries business performance
The company's return on invested capital has surged by 166% YoY but it fell by 37% QoQ
Teva Pharmaceutical Industries's return on sales has surged by 155% YoY but it has decreased by 40% QoQ
TEVA's ROE has plunged by 112% from the previous quarter but it has soared by 54% YoY
Teva Pharmaceutical Industries's return on assets has shrunk by 109% QoQ but it has surged by 57% YoY
Dividends
What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Teva Pharmaceutical Industries financials performed over time
The total assets is 18% greater than the total liabilities
Teva Pharmaceutical Industries's current ratio has decreased by 11% YoY
TEVA's quick ratio is up by 7% from the previous quarter
Teva Pharmaceutical Industries's equity has decreased by 12% YoY and by 4.6% QoQ
TEVA's debt to equity is up by 9% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.